Recall(New to the series?)
Single GLP-1 agonists hit one receptor: GLP-1R. That drives insulin secretion, glucagon suppression, gastric slowing, and appetite reduction through the brain. For the full receptor breakdown, see The Receptor Game.
Single GLP-1 receptor agonists are where the class started. Before dual agonists, before oral non-peptides, before triple agonism — these drugs demonstrated that mimicking an endogenous gut hormone could produce clinically meaningful weight loss and glycemic control at scale. They also defined what the ceiling looks like, which turned out to be the most important thing they did.
The proof of concept
The class began with exenatide in 2005 — derived from a peptide found in Gila monster saliva that happened to resist the enzyme that degrades native GLP-1. It worked. Not dramatically, but enough to prove that GLP-1R agonism was clinically real and tolerable. Liraglutide followed with better efficacy and once-daily dosing. Dulaglutide pushed to once-weekly.
Semaglutide is where the ceiling became visible. At 2.4mg weekly (Wegovy), it achieved ~15% mean weight loss in the STEP 1 trial — a number that had never been seen from a pharmacological agent in a large Phase 3 trial. It also showed 20% reduction in major cardiovascular events in the SELECT trial, expanding the drug from metabolic disease into cardiology.
That 15% number is both the achievement and the constraint. It represents what single GLP-1R agonism can do at its current dose limit. Getting meaningfully past it requires either tolerating more GI side effects at higher doses, or targeting additional receptors — which is what the next three posts in this series are about.
What defines single GLP-1 agonism
One receptor, multiple effects — GLP-1R is expressed in the pancreas, brain, gut, heart, and kidneys. A single receptor activation drives insulin secretion, glucagon suppression, gastric slowing, and appetite reduction simultaneously. This broad effect profile is why GLP-1 drugs work across multiple endpoints (glycemia, weight, cardiovascular outcomes).
The GI signature — nausea, vomiting, and diarrhea during dose escalation are a direct consequence of GLP-1R's role in slowing gastric motility. This is the class trademark. It's highest during titration and typically self-resolves. Every drug in this family shares it.
The efficacy ceiling — roughly 15% weight loss at the highest commercially viable doses. Not a hard biological ceiling — higher doses push past it — but the GI burden at those doses limits practical use. The ceiling is what motivated dual and triple agonism.
Drugs in this family
Each drug below has its own profile covering mechanism, trial data, dosing, development status, and safety.
- Semaglutide — Ozempic / Wegovy / Rybelsus — the current standard of care
- Liraglutide — Saxenda / Victoza — once-daily predecessor, first CV outcome data
- Exenatide — Byetta / Bydureon — the original, derived from Gila monster peptide
- Dulaglutide — Trulicity — once-weekly Fc-fusion approach
- Ecluglutide — China-approved, first cAMP-biased GLP-1R agonist
Summary(The single agonist picture)
Single GLP-1 agonists proved the class works and gave us semaglutide as the commercial benchmark. The ~15% weight loss ceiling is real, the cardiovascular benefit is real, and the GI tolerability signature is real. Everything in the next four posts exists because of what this family established — and because of where it stopped.